Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema

Özkırış, Abdullah

doi:10.1038/eye.2008.40

Cited by 29 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Functional and anatomical outcomes are comparable to those of other studies, including the use of other anti-VEGF agents, i.e. bevacizumab [12,13,14,15,16,17,18,19,20,21,22]. The BOLT study provided no evidence of worsening of macular ischemia in DME patients treated with intravitreal bevacizumab [20].…”

Section: Discussionsupporting

confidence: 65%

“…There have been several studies showing improvement in VA as well as reduction in macular edema in patients treated with intravitreal anti-VEGF agents, especially bevacizumab, against DME [12,13,14,15,16,17,18,19,20,21,22]. Recent studies have also demonstrated that ranibizumab, another anti-VEGF agent, exhibited a positive effect on DME [6,23,24,25].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Macular Ischemia on Intravitreal Ranibizumab Treatment for Diabetic Macular Edema

Douvali

Chatziralli²,

Theodossiadis³

et al. 2014

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To evaluate the impact of macular ischemia on the functional and anatomical outcome after intravitreal injections of ranibizumab for the treatment of diabetic macular edema (DME). Procedures: Participants were 49 patients with diabetes mellitus, divided into two groups based on the presence of ischemia on fluorescein angiography: (i) nonischemic group (n = 32) and (ii) ischemic group (n = 17). All patients were treated with intravitreal ranibizumab and were followed up for 6 months. The main outcome measures were changes in visual acuity (VA) and central foveal thickness (CFT). Results: There was a statistically significant improvement in VA and CFT between baseline and the end of the follow-up in the nonischemic group, while in the ischemic group there was no significant difference in VA but CFT differed significantly at the 6-month follow-up. Conclusions: Macular ischemia may have a negative impact on functional outcomes 6 months after intravitreal ranibizumab treatment in patients with DME but has no effect on anatomical outcomes.

show abstract

Section: Discussionsupporting

confidence: 65%

Section: Introductionmentioning

confidence: 99%

Effect of Macular Ischemia on Intravitreal Ranibizumab Treatment for Diabetic Macular Edema

Douvali

Chatziralli²,

Theodossiadis³

et al. 2014

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Some studies also used it in combination with laser with improved success and some in DME refractory to other treatment modalities with success. [17][18][19][20][21] In the present study, leakage from neovascular area significantly decreased following intravitreal injection of bevacizumab on angiogram and was minimum at 4 weeks. Authors found an increase in leakage area similar to rebound increase in leakage area in DME at 8 weeks and this leakage area also further increased at 12 weeks, but net decrease remain statistically significant at 12 weeks.…”

Section: Resultssupporting

confidence: 55%

“…Success was noted in all such cases. [17][18][19][21][22][23][24] Pan retinal photocoagulation (PRP) is currently the principal therapy for PDR, unless the patient already has extensive vitreous hemorrhage, which would preclude the possibility of laser photocoagulation. Neovascularization at disc (NVD) and vitreous hemorrhage were found to be more frequently associated with severe visual loss despite PRP in the Diabetic Retinopathy Study (DRS) and Early Treatment Diabetic Retinopathy Study (ETDRS).…”

Section: Resultsmentioning

confidence: 99%

Fundus fluorescein angiographic assessment of patients with proliferative Diabetic Retinopathy and Macular Edema before and after intravitreal injection of Bevacizumab

Ankur¹,

Kumar

Arora³

et al. 2019

Int J Res Med Sci

View full text Add to dashboard Cite

Background: To assess the role of intravitreal bevacizumab (1.25 mg) in patients with proliferative diabetic retinopathy with macular edema in terms of change in leakage area and best-corrected visual acuity.Methods: This prospective randomized interventional study was conducted in the Department of Ophthalmology from September 2013 to August 2015 and included thirty eyes of twenty patients.After a detailed history and ocular examination, diagnosed cases of proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME) underwent sequential fundus fluorescein angiography. Bevacizumab was administered intravitreally. Patients were assessed two hours after injection for anterior chamber reaction and intraocular pressure and were advised follow-ups at 24 hours and then at 1, 4, 8 and 12 weeks. For the outcome, the change of retinal new vessels by assessment of leakage area using Quantitative Planimetric Analysis (QPA) of photographs as well as the change in best-corrected visual acuity (BCVA) from baseline to the 12 weeks follow-up, were done. Results were analyzed statistically by applying t-test.Results: Intravitreal bevacizumab injection lead to a significant decrease in leakage in DME and PDR, and improvement in mean BCVA. The effect was maximum at 4 weeks which weaned off as the study progressed through it remains statistically significant at the end of 12 weeks.Conclusions: Intravitreal bevacizumab plays a major role in treating and reducing visual deterioration in patients with proliferative diabetic retinopathy and diabetic macular edema.

show abstract

“…All three are gaining popularity as an adjunct to photocoagulation in proliferative DR and diabetic macular oedema , or in combination with anti‐inflammatory drugs, particularly triamcinolone acetonide . Recently, they have also been tried as primary care treatments . More than 50 000 patients have been treated with pegaptanib in 1 year in the USA alone .…”

Section: Anti‐dr Drug Treatments Used Currently In Clinical Practicementioning

confidence: 99%

Neuropeptides and diabetic retinopathy

Gábriel¹

2013

Brit J Clinical Pharma

View full text Add to dashboard Cite

Diabetic retinopathy, a common complication of diabetes, develops in 75% of patients with type 1 and 50% of patients with type 2 diabetes, progressing to legal blindness in about 5%. In the recent years, considerable efforts have been put into finding treatments for this condition. It has been discovered that peptidergic mechanisms (neuropeptides and their analogues, activating a diverse array of signal transduction pathways through their multiple receptors) are potentially important for consideration in drug development strategies. A considerable amount of knowledge has been accumulated over the last three decades on human retinal neuropeptides and those elements in the pathomechanisms of diabetic retinopathy which might be related to peptidergic signal transduction. Here, human retinal neuropeptides and their receptors are reviewed, along with the theories relevant to the pathogenesis of diabetic retinopathy both in humans and in experimental models. By collating this information, the curative potential of certain neupeptides and their analogues/antagonists can also be discussed, along with the existing clinical treatments of diabetic retinopathy. The most promising peptidergic pathways for which treatment strategies may be developed at present are stimulation of the somatostatin-related pathway and the pituitary adenylyl cyclase-activating polypeptide-related pathway or inhibition of angiotensinergic mechanisms. These approaches may result in the inhibition of vascular endothelial growth factor production and neuronal apoptosis; therefore, both the optical quality of the image and the processing capability of the neural circuit in the retina may be saved.

show abstract

Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema

Cited by 29 publications

References 32 publications

Effect of Macular Ischemia on Intravitreal Ranibizumab Treatment for Diabetic Macular Edema

Effect of Macular Ischemia on Intravitreal Ranibizumab Treatment for Diabetic Macular Edema

Fundus fluorescein angiographic assessment of patients with proliferative Diabetic Retinopathy and Macular Edema before and after intravitreal injection of Bevacizumab

Neuropeptides and diabetic retinopathy

Contact Info

Product

Resources

About